Skip to main content
SpringerLink
Log in
Book cover

Hodgkin Lymphoma pp 163–181Cite as

Treatment of Early Favorable Hodgkin Lymphoma

  • Chapter
  • First Online:

  • 1121 Accesses

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Most research groups define favorable early Hodgkin lymphoma (HL) as stage I–II disease without risk factors. The vast majority of these patients can be cured with chemotherapy, radiotherapy, or with combined modality approaches. Before the introduction of combined modality approaches, large-field radiotherapy had resulted in very good tumor control, but relapses occurred in approximately 30% of patients, with most recurrences outside the radiation field. Later, combined modality approaches were employed to overcome the problem of out-of-field relapses and because of concern on the long-term toxicity of radiotherapy. Since then, the ABVD regimen has become the standard first-line treatment in most countries and cooperative groups due to its favorable toxicity profile when compared with alkylating-agent-based regimens. Emerging data on late toxicity of radiotherapy resulted in the application of smaller field sizes and lower radiation doses. The current standard of care is a limited number of ABVD cycles (two to three cycles) followed by 20 or 30 Gy involved field radiotherapy. Current focus is on the role of PET imaging and whether a response-adapted approach guided by PET can individualize therapy so that radiotherapy can be avoided in subsets of patients

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.

    PubMed  CAS  Google Scholar 

  2. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.

    PubMed  CAS  Google Scholar 

  3. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V; German Hodgkin’s Lymphoma Study Group. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. J Clin Oncol. 1995;13:403–9.

    Google Scholar 

  4. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of HL. Crit Rev Oncol Hematol. 2004;52:19–32.

    Article  PubMed  Google Scholar 

  5. Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006;91:482–9.

    PubMed  Google Scholar 

  6. Juweid ME (2006) Utility of positron emission tomography (PET) scanning in managing patients with HL. Hematology Am Soc Hematol Educ Program. 259–65.

    Google Scholar 

  7. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.

    Article  PubMed  Google Scholar 

  8. Specht L, Nissen NI. Hodgkin’s disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur J Haematol. 1988;40:396–402.

    Article  PubMed  CAS  Google Scholar 

  9. Specht L. Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol. 1996;6:146–61.

    Article  PubMed  Google Scholar 

  10. Tubiana M, Henry-Amar M, van der Werf-Messing B, Henry J, Abbatucci J, Burgers M, et al. A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1985;11:23–30.

    Article  PubMed  CAS  Google Scholar 

  11. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early stage Hodgkin’s disease. N Engl J Med. 2007;357:1916–27.

    Article  PubMed  Google Scholar 

  12. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25:3495–502.

    Article  PubMed  CAS  Google Scholar 

  13. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS. The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 1982;59:455–65.

    PubMed  CAS  Google Scholar 

  14. Gospodarowicz MK, Sutcliffe SB, Clark RM, Dembo AJ, Fitzpatrick PJ, Munro AJ, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys. 1992;22:859–65.

    Article  PubMed  CAS  Google Scholar 

  15. Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38 Suppl 4:S107–13.

    Article  PubMed  Google Scholar 

  16. Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73:47–56.

    PubMed  CAS  Google Scholar 

  17. Tubiana M, Henry-Amar M, Hayat M, Breur K, van der Werf-Messing B, Burgers M. Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin’s disease. Eur J Cancer. 1979;15:645–57.

    PubMed  CAS  Google Scholar 

  18. Tubiana M, Hayat M, Henry-Amar M, Breur K, van der Werf MB, Burgers M. Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer. 1981;17:355–63.

    PubMed  CAS  Google Scholar 

  19. Carde P, Burgers JM, Henry-Amar M, Hayat M, Sizoo W, Van der Schueren E, et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6:239–52.

    PubMed  CAS  Google Scholar 

  20. Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11:2258–72.

    PubMed  CAS  Google Scholar 

  21. Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Ruhl U, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol. 2001;19:2905–14.

    PubMed  Google Scholar 

  22. Noordijk EM, Carde P, Hagenbeek A, Mandard AM, Kluin-Nelemans JC, Thomas J, et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease six-year results of the EORTC-GPMC controlled clinical trials H7-VF, H7-F and H7-U. Int J Radiat Oncol Biol Phys. 1997;39:173.

    Article  Google Scholar 

  23. Specht L, Gray RG, Clarke MJ, Peto R; International Hodgkin’s Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 1998;16:830–43.

    Google Scholar 

  24. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer. 1997;33:848–53.

    Article  PubMed  CAS  Google Scholar 

  25. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–9.

    Article  PubMed  Google Scholar 

  26. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–8.

    Article  PubMed  Google Scholar 

  27. Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van’t Veer MB, Aleman BM, et al. Survival after HL: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115:1680–91.

    Article  PubMed  Google Scholar 

  28. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.

    Article  PubMed  CAS  Google Scholar 

  29. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19:4238–44.

    PubMed  CAS  Google Scholar 

  30. Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol. 1997;15:1736–44.

    PubMed  CAS  Google Scholar 

  31. Zittoun R, Audebert A, Hoerni B, Bernadou A, Krulik M, Rojouan J, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol. 1985;3:207–14.

    PubMed  CAS  Google Scholar 

  32. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.

    Article  PubMed  Google Scholar 

  33. Engert A, Diehl V, Pluetschow A, Eich H, Herrmann R, Doerken B, et al. Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early stage HL: Final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Blood. 2009;114:716.

    Google Scholar 

  34. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–7.

    Article  PubMed  Google Scholar 

  35. Noordijk E, Thomas J, Ferme C, van’t Veer M, Brice P, Divine M, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and the H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol. 2005;23:6505.

    Google Scholar 

  36. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21:3601–8.

    Article  PubMed  Google Scholar 

  37. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22:2835–41.

    Article  PubMed  Google Scholar 

  38. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early HL: concepts and guidelines. Radiother Oncol. 2006;79:270–7.

    Article  PubMed  Google Scholar 

  39. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol. 2006;78:1–5.

    Article  PubMed  Google Scholar 

  40. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, et al. The conundrum of HL nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol. 2008;88:202–10.

    Article  PubMed  Google Scholar 

  41. Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26:5170–4.

    Article  PubMed  Google Scholar 

  42. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ, et al. Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991;9:906–17.

    PubMed  CAS  Google Scholar 

  43. Biti GP, Cimino G, Cartoni C, Magrini SM, Anselmo AP, Enrici RM, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol. 1992;10:378–82.

    PubMed  CAS  Google Scholar 

  44. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–42.

    Article  PubMed  CAS  Google Scholar 

  45. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483–9.

    Article  PubMed  CAS  Google Scholar 

  46. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  PubMed  CAS  Google Scholar 

  47. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in HL. Ann Oncol. 2005;16:1160–8.

    Article  PubMed  CAS  Google Scholar 

  48. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in HL. Blood. 2006;107:52–9.

    Article  PubMed  CAS  Google Scholar 

  49. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin’s and non-Hodgkin’s lymphoma. Curr Opin Oncol. 2008;20:206–19.

    Article  PubMed  Google Scholar 

  50. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10:1160–70.

    Article  PubMed  Google Scholar 

  51. Brepoels L, Stroobants S. PET scanning and prognosis in Hodgkin’s lymphoma. Curr Opin Oncol. 2008;20:509–16.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Erasmus MC, University Medical Center, 2040, 3000 CA, Rotterdam, The Netherlands

    Elly Lugtenburg

  2. Department of Haematology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Anton Hagenbeek

Authors
  1. Elly Lugtenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anton Hagenbeek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elly Lugtenburg .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lugtenburg, E., Hagenbeek, A. (2011). Treatment of Early Favorable Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation